Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Compumedics Limited ( (AU:CMP) ) has provided an update.
Compumedics Limited announced a correction to its financial guidance for FY25, expecting sales orders to exceed $60 million, with reported revenues between $50 million and $55 million, which is below the previously advised $55 million. The company anticipates an EBITDA of about $3 million for FY25, down from the previously advised $5 million. Looking ahead, Compumedics confirms FY26 revenue guidance of at least $70 million, driven by the shipment of MEG orders, with an expected EBITDA of at least $9 million.
More about Compumedics Limited
Compumedics Limited is a global medical device company specializing in the development, manufacturing, and commercialization of diagnostic technology for sleep, brain, and ultrasonic blood flow monitoring. The company, founded by Dr. David Burton in 1987, has a significant international presence through its subsidiaries Neuroscan in the US and DWL Elektronishe GmbH in Germany. Compumedics has been recognized for its innovation and export achievements, including being listed on the Australian Securities Exchange in 2000.
Average Trading Volume: 95,231
Technical Sentiment Signal: Sell
Current Market Cap: A$54.78M
Learn more about CMP stock on TipRanks’ Stock Analysis page.